- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Analogic and Philips strike new deal
Analogic of Peabody, MA, has struck a multiyear, multimillion dollar agreement to develop and provide advanced engineering and manufacturing services to Philips Medical Systems. The agreement calls for Analogic to develop new subassemblies/components for
Analogic of Peabody, MA, has struck a multiyear, multimillion dollar agreement to develop and provide advanced engineering and manufacturing services to Philips Medical Systems. The agreement calls for Analogic to develop new subassemblies/components for Philips, while continuing to supply data acquisition systems, spare parts, and engineering services for the CT systems previously provided by Analogic and sold by Philips. Analogic will also continue supplying a range of patient monitoring equipment to Philips. Until Philips' acquisition of Marconi Medical last year, Analogic had been the Dutch company's sole supplier of midrange CT systems. After the Marconi purchase, however, Philips and Analogic decided to restructure the existing CT contract and develop a new agreement.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
